AbbVie Launches $70M Expansion At Bioresearch Center To Boost Biologics Production;Expands U.S. Biologics Manufacturing In Worcester

AbbVie has announced the commencement of a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, a hub for biologics research, development, and manufacturing. This expansion is part of AbbVie’s broader commitment to invest over $10 billion in the U.S. to support innovation and expand critical biologics manufacturing capabilities and capacity.

"For more than three decades, ABC has been at the forefront of scientific innovation and biologics manufacturing," said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. "This investment will further expand AbbVie's biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide."

The project will enhance AbbVie’s domestic biologics production to meet growing global demand and support U.S. manufacturing of both current and next-generation oncology and immunology therapies. The expansion includes new biologics manufacturing areas and a three-story building with laboratories, warehouse space, and offices, facilitating the faster transfer of select oncology products from Europe to the U.S.

AbbVie has a nationwide presence with 28,000 U.S. employees, including over 2,000 in Massachusetts. The expansion is expected to create new jobs at the ABC site while further strengthening AbbVie’s domestic manufacturing footprint, which currently supports more than 6,000 jobs across 11 U.S. facilities.